Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
USV Private Limited is a pharmaceutical company specializing in the development and manufacturing of high-quality generic medicines and active pharmaceutical ingredients. It offers a diverse range of products, including formulations for therapeutic areas such as cardiology, diabetes, and gynecology, aimed at improving healthcare access and outcomes.
Usv Private Limited, is an unlisted private company incorporated on 25 August, 1961. It is classified as a private limited company and is located in , Maharashtra. It's authorized share capital is INR 125.00 cr and the total paid-up capital is INR 91.59 cr.
Read more
** All rupee values in INR crores. Based on March 2025 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Leena Gandhi Tewari
Shareholder
|
00001748 | 40 years |
| Director | Murugappan Muthiah Venkatachalam | 00152619 | 19 years |
| Director | Vilas Gandhi Tewari
Shareholder
|
05354249 | 13 years |
| Director | Debabrata Bhadury | 00001754 | 25 years |
| Managing Director | Prashant Kumar Tewari
Shareholder
|
00001745 | 18 years |
| Whole-time Director | Jayant Dwivedy | 02833134 | 8 years |
| Director | Aneesha Gandhi Tewari
Shareholder
|
06910549 | 3 years |
| Director | Debabrata Sujit Gupta | 01500784 | 2 years |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | 3,591.4 | 3,831.1 | 4,111.7 | 4,475.6 | 4,750.4 |
| Operating profit | 1,421.1 | 1,459.0 | 1,597.5 | 1,706.2 | 1,804.5 |
| Net profit | 1,052.5 | 1,081.9 | 1,130.3 | 1,325.4 | 1,457.2 |
| Gross margin | 75.6 | 76.1 | 77.8 | 78.9 | 80.0 |
| Operating margin | 39.6 | 38.1 | 38.9 | 38.1 | 38.0 |
| Net margin | 28.2 | 27.3 | 26.5 | 27.9 | 28.4 |
| Networth | 3,607.1 | 3,973.7 | 4,412.7 | 5,150.3 | 6,230.5 |
| Borrowings | - | - | - | - | - |
| Assets | 4,311.7 | 4,639.4 | 5,112.7 | 5,925.9 | 7,096.9 |
| Debt to equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current ratio | 3.7 | 4.2 | 4.3 | 3.9 | 3.9 |
| ROE | 29.2 | 27.2 | 25.6 | 25.7 | 23.4 |
| Days payable | 122.0 | 112.0 | 122.0 | 118.0 | 123.0 |
| WC days | 163.0 | 164.0 | 161.0 | 144.0 | 144.0 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 97.9 | 95.3 | 93.3 | 91.6 | 91.6 |
| Reserves | 3,509.2 | 3,878.4 | 4,319.4 | 5,058.7 | 6,138.9 |
| Borrowings + | - | - | - | - | - |
| Long term borrowings | - | - | - | - | - |
| Short term borrowings | - | - | - | - | - |
| Trade payables + | 292.8 | 281.4 | 304.8 | 306.4 | 319.5 |
| Days payable | 122.0 | 112.0 | 122.0 | 118.0 | 123.0 |
| Other liabilities + | 704.6 | 665.7 | 700.0 | 775.6 | 866.4 |
| Other non-current liabilities | 115.7 | 126.5 | 155.2 | 165.7 | 226.0 |
| Other current liabilities | 296.1 | 257.8 | 239.9 | 303.4 | 320.9 |
| Total liabilities | 4,311.7 | 4,639.4 | 5,112.7 | 5,925.9 | 7,096.9 |
| Fixed Assets + | 1,127.1 | 1,267.2 | 1,256.2 | 1,182.2 | 1,028.4 |
| Tangible assets | 487.1 | 449.5 | 897.7 | 922.1 | 822.4 |
| CWIP | 260.5 | 467.0 | 105.3 | 43.0 | 26.8 |
| Intangible assets | 379.5 | 350.7 | 253.1 | 217.1 | 179.2 |
| LT loans and advances | 2.7 | 0.2 | 0.1 | 0.1 | 0.1 |
| Other non-current assets | 985.5 | 1,107.1 | 1,500.3 | 2,367.4 | 3,554.2 |
| Current assets + | 2,196.4 | 2,264.9 | 2,356.1 | 2,376.2 | 2,514.2 |
| Inventories | 319.4 | 404.9 | 371.3 | 334.5 | 357.9 |
| Trade receivables | 345.7 | 295.5 | 371.4 | 363.8 | 379.2 |
| Cash and cash equivalents | 80.8 | 60.1 | 52.8 | 71.8 | 75.1 |
| ST loans and advances | 10.3 | 3.3 | 2.7 | 3.1 | - |
| Other current assets | 1,440.2 | 1,501.1 | 1,557.9 | 1,602.9 | 1,702.0 |
| Total assets | 4,311.7 | 4,639.4 | 5,112.7 | 5,925.9 | 7,096.9 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales + | 3,591.4 | 3,831.1 | 4,111.7 | 4,475.6 | 4,750.4 |
| Sales growth % | 14.34 | 6.67 | 7.33 | 8.85 | 6.14 |
| Expenses + | 2,326.0 | 2,514.8 | 2,751.0 | 3,018.6 | 3,192.7 |
| Cost of goods | 874.8 | 914.4 | 913.4 | 944.5 | 951.7 |
| Employee cost | 476.4 | 519.5 | 583.4 | 729.2 | 819.6 |
| Other costs | 819.1 | 938.2 | 1,017.4 | 1,095.7 | 1,174.6 |
| Operating profit + | 1,421.1 | 1,459.0 | 1,597.5 | 1,706.2 | 1,804.5 |
| Operating margin % | 39.6 | 38.1 | 38.9 | 38.1 | 38.0 |
| Other income | 143.3 | 129.7 | 147.3 | 273.6 | 384.9 |
| Interest | 1.3 | 1.4 | 2.7 | 3.0 | 3.2 |
| Depreciation | 154.3 | 141.2 | 234.1 | 246.3 | 243.5 |
| Exceptional items | - | - | - | - | - |
| Profit before tax | 1,408.8 | 1,446.0 | 1,508.0 | 1,730.5 | 1,942.7 |
| Tax | 356.3 | 364.1 | 377.7 | 405.1 | 485.5 |
| Profit - disc. ops | - | - | - | - | - |
| Net profit | 1,052.5 | 1,081.9 | 1,130.3 | 1,325.4 | 1,457.2 |
| Net margin % | 28.2 | 27.3 | 26.5 | 27.9 | 28.4 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Debt/Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Debt/Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Assets/Equity | 1.2 | 1.2 | 1.2 | 1.1 | 1.1 |
| Liquidity + | |||||
| Current Ratio | 3.7 | 4.2 | 4.3 | 3.9 | 3.9 |
| Quick Ratio | 3.2 | 3.5 | 3.6 | 3.4 | 3.4 |
| Interest Coverage | 1,060.5 | 1,020.3 | 589.5 | 574.5 | 557.0 |
| Performance | |||||
| Gross Margin | 75.6 | 76.1 | 77.8 | 78.9 | 80.0 |
| Operating Margin | 39.6 | 38.1 | 38.9 | 38.1 | 38.0 |
| Net Margin | 28.2 | 27.3 | 26.5 | 27.9 | 28.4 |
| Return + | |||||
| Return on Equity | 29.2 | 27.2 | 25.6 | 25.7 | 23.4 |
| Pre-tax ROCE | 46.3 | 44.0 | 44.5 | 49.5 | 53.8 |
| Return on Assets | 24.4 | 23.3 | 22.1 | 22.4 | 20.5 |
| Pre-tax ROIC | 35.1 | 33.2 | 30.9 | 28.4 | 25.1 |
| Efficiency + | |||||
| Days Payable | 122.0 | 112.0 | 122.0 | 118.0 | 123.0 |
| Days Inventory | 133.0 | 162.0 | 148.0 | 129.0 | 137.0 |
| Days Receivable | 35.0 | 28.0 | 33.0 | 30.0 | 29.0 |
| Fixed Asset Turnover | 3.2 | 3.0 | 3.3 | 3.8 | 4.6 |
| Total Asset Turnover | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 |
| Working Capital | |||||
| Cash Conversion Cycle | 46.0 | 78.0 | 59.0 | 41.0 | 43.0 |
| Working Capital Days | 163.0 | 164.0 | 161.0 | 144.0 | 144.0 |
As per information available, the company has no registered charges.
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| USV North America Inc. | United States | - | - |
| Indicus Pharma LLC | United States | - | - |
| USV UK Limited | United Kingdom | - | - |
| Juta Pharma GmbH | Germany | - | - |
| USV Philippines Inc. | Philippines | - | - |
Read more
The incorporation date of USV PRIVATE LIMITED is 25 August, 1961
The authorized share capital of USV PRIVATE LIMITED is INR ₹ 125.0 Cr.
The paid-up capital of USV PRIVATE LIMITED is INR ₹ 91.6 Cr.
The registered address of USV PRIVATE LIMITED is Arvind Vithal Gandhi Chowk, B S D Marg, Govandi, Mumbai, Maharashtra, India, 400088 - 400088
The CIN number of USV PRIVATE LIMITED is U24239MH1961PTC012098.